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Abstract
b-Elemene is an active component of the herb medicine Curcuma Wenyujin with reported antitumor activity. To improve its
antitumor ability, five novel piperazine derivatives of b-elemene, 13-(3-methyl-1-piperazinyl)-b-elemene (DX1), 13-(cis-3,5-
dimethyl-1-piperazinyl)-b-elemene (DX2), 13-(4-ethyl-1-piperazinyl)-b-elemene (DX3), 13-(4-isopropyl-1-piperazinyl)-b-ele-
mene (DX4) and 13-piperazinyl-b-elemene (DX5), were synthesized. The antiproliferative and apoptotic effects of these
derivatives were determined in human leukemia HL-60, NB4, K562 and HP100-1 cells. DX1, DX2 and DX5, which contain a
secondary amino moiety, were more active in inhibiting cell growth and in inducing apoptosis than DX3 and DX4. The
apoptosis induction ability of DX1 was associated with the generation of hydrogen peroxide (H2O2), a decrease of
mitochondrial membrane potential (MMP), and the activation of caspase-8. Pretreatment with the antioxidants N-
acetylcysteine and catalase completely blocked DX1-induced H2O2 production, but only partially its activation of caspase-8
and induction of apoptosis. HL-60 cells were more sensitive than its H2O2-resistant subclone HP100-1 cells to DX1-induced
apoptosis. The activation of caspase-8 by these compounds was correlated with the decrease in the levels of cellular FLICE-
inhibitory protein (c-FLIP). The proteasome inhibitor MG-132 augmented the decrease in c-FLIP levels and apoptosis
induced by these derivatives. FADD- and caspase-8-deficient Jurkat subclones have a decreased response to DX1-induced
apoptosis. Our data indicate that these novel b-elemene piperazine derivatives induce apoptosis through the decrease in c-
FLIP levels and the production of H2O2 which leads to activation of both death receptor- and mitochondrial-mediated
apoptotic pathways.
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Introduction
b-Elemene is one of the active components in the essential oil of
Curcuma Wenyujin, a traditional Chinese herb medicine. b-Elemene
has been shown to inhibit tumor cell growth in vitro and in vivo and
has been put into clinical trials in cancer patients in China [1,2,3].
However, due to its poor water-solubility and the requirement of
high concentrations to reach therapeutic effects, the efficacy of b-
elemene in cancer treatment is limited. To improve its activity we
have synthesized a series of b-elemene derivatives which contain
piperazine, morpholine, tetrahydropyrrole, thiophenylethylamine,
or cyclohexamine groups [4]. Among these derivatives, 13,14-
bis(cis-3,5-dimethyl-1-piperazinyl)-b-elemene was found to be one
of the most potent agents in inhibiting the growth of leukemia cells
[4].
Based on these previous observations, five novel b-elemene
derivatives with substitution of one different piperazinyl group, 13-
(3-methyl-1-piperazinyl)-b-elemene (DX1), 13-(cis-3,5-dimethyl-1-
piperazinyl )-b-elemene (DX2), 13-(4-ethyl-1-piperazinyl)-b-ele-
mene (DX3), 13-(4-isopropyl-1-piperazinyl)-b-elemene (DX4) and
13-piperazinyl-b-elemene (DX5), were synthesized. The abilities of
these compounds to inhibit cell growth and to induce apoptosis as
well as their mechanisms of apoptosis induction were investigated
in several human leukemia cell lines. All of the five compounds
inhibited cell growth with IG50s less than 10 mM. Compounds
with a secondary amino moiety (DX1, DX2 and DX5) were more
potent than compounds without a secondary amino moiety (DX3
and DX4) in inducing apoptosis. Mechanism studies of apoptosis
induction revealed that both the mitochondrial- and the death
receptor-mediated apoptotic pathways were involved. The mito-
chondrial apoptotic pathway is activated due to cleavage of Bid by
activated caspase-8 and by the production of reactive oxygen
species (ROS). The role of ROS in the apoptosis induction by
these compounds was investigated using antioxidants and a H2O2-
resistant cell line. The activation of caspase-8 was investigated by
assessing levels of the death receptors and the cellular FLICE-
inhibitory protein (c-FLIP). Jurkat cells deficient of Fas-associated
death domain protein (FADD) and caspase-8 were used to
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15843evaluate the role of caspase-8 activation in the apoptosis induction
due to these compounds. Our data suggest that these novel b-
elemene derivatives induce apoptosis through both the death
receptor- and the mitochondrial-mediated apoptotic pathways due
to down-regulation of c-FLIP protein and the production of ROS,
respectively.
Materials and Methods
Reagents
DX1-DX5 were synthesized using similar methods to those that
we reported previously [4] and were prepared as maleates. The
chemical structures were characterized with IR spectroscopy,
1H-
NMR spectroscopy, mass spectrometry, and elemental analyses.
N-acetylcysteine (NAC), ethidium bromide (EB), acridine orange
(AO), propidium iodide (PI), catalase (CAT) and TRAIL receptor
2/Fc chimera (TRAIL R2/Fc) were purchased from Sigma
Chemical Co. (St. Louis, MO). Rhodamine-123 (Rh123) and 5,6-
carboxy-29,79-dichlorodihydrofluorescein diacetate (DCFH-DA)
were obtained from Molecular Probes (Eugene, OR). Antibody
to poly-(ADP-ribose)-polymerase was obtained from Boehringer
Mannheim (Indianapolis, IN), antibodies to caspase-3, caspase-8
and CD95L were from BD Biosciences (San Diego, CA),
antibodies to DR4, DR5 and c-FLIP were from Alexis
Biochemicals (San Diego, CA), antibodies to Bid, NOK-1,
CD95 and b-actin were from Santa Cruz Biotechology, Inc.
(Santa Cruz, CA), and antibodies to caspase-9 and TRAIL were
from Cell Signaling Technology (Beverly, MA).
Cell lines. HL-60, NB4 and K562 cells were cultured in
RPMI-1640 medium supplemented with 100 units/mL penicillin,
100 mg/mL streptomycin, 1 mmol/L L-glutamine, and 10% (v/v)
heat-inactivated fetal bovine serum (FBS) as we described
previously [5]. HP100-1 (obtained from the Japanese Cell Bank)
is a H2O2-resistant subclone of HL-60 cells [6]. Jurkat subclones,
A3, FADD-deficient I 9.1, and caspase-8-deficient I 9.2 were
obtained from ATCC and were cultured in RPMI 1640
supplemented with 10% heat-inactivated FBS [7].
Cell growth inhibition. Cells were seeded at 1610
5 cells/
mL and incubated with various concentrations of b-elemene
piperazine derivatives for 72 h. Total cell number was determined
with the aid of a hemocytometer and cell viability was estimated
by trypan blue exclusion [8].
MTT assay. Two hundred mL of HL-60 cells at a density of
1610
5/ml containing variousconcentrations of DX1 were plated in
each well of 96-well plates. The cells were cultured for 12 and 24 h
at 37uC. 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) solution (50 ml of 2 mg/ml) was added per well
and the cultures were continued for an additional 4 h. The medium
was aspirated after centrifugation at 1000 RPM for 10 min, the cells
were dissolved in 100 ml DMSO, and the optical density (OD) at
570 nm was determined in each well with a 96-well plate reader.
The cytotoxicity was calculated as ODt/ODc6100%. ODc
represents the OD of the control group and ODt represents the
OD of the treated group.
Quantitation of apoptotic cells. Apoptotic cells were
determined by morphologic observation, fluorescence-activated
cell sorting (FACS) analysis after staining with PI, and Annexin V/
PI. [8]. For morphologic observation, cells were stained with AO
and EB and assessed by fluorescence microscopy as described
previously [8]. Briefly, 1 mL of stock solution containing 100 mg/
mL AO and 100 mg/mL EB was added to 25 mL of cell
suspension. EB-negative cells with nuclear shrinkage, blebbing
and apoptotic bodies were counted as apoptotic cells. The
percentage of apoptotic cells was calculated after observing a
total of 300 cells. For FACS analysis with PI staining, cells were
fixed with ice-cold 70% ethanol at a density of 1610
5 cells/mL
and treated with 200 mg/mL RNase for 30 min at 37uC. PI was
then added to the solution at a final concentration of 50 mg/mL
and the DNA content was quantitated by flow cytometry (Becton
Dickinson, San Jose, CA) with an excitation wavelength of 488 nm
and an emission wavelength of 625 nm. Data were analyzed using
CELLQuest (Becton Dickinson) software. For the annexin V
staining analysis, 10
5 cells were washed twice with PBS, then
labeled with annexin V-FITC and PI in binding buffer according
to the instructions provided by the manufacturer in the Annexin
V-FITC Apoptosis Detection Kit (Oncogene, Cambridge, MA).
The fluorescent signals of FITC and PI were detected at 518 nm
and at 625 nm, respectively, with a flow cytometer. Data were
analyzed using CELLQuest (Becton Dickinson) software.
Quantification of DNA fragmentation. DNA fragmen-
tation was quantified as described previously [5]. Cells were
harvested by centrifugation, and the pellets were suspended in lysis
buffer containing 15 mmol/L Tris?HCl, 20 mmol/L EDTA,
0.5% Triton X-100, pH 8.0. After 30 min on ice, samples were
centrifuged at 14,000g for 30 min, and cellular DNA was
extracted. Electrophoresis was performed in 1% agarose gel in
40 mmol/L Tris-acetate buffer (pH 7.4) at 50 V. After
electrophoresis, DNA was visualized by EB staining.
Determination of intracellular H2O2. Intracellular H2O2
was monitored by flow cytometry after staining with DCFH-DA.
In the present study, cells were labeled with 5 mM DCFH-DA for
1 h and then treated with or without b-elemene piperazine
derivatives at 37uC for various times. After washing with
phosphate buffer saline (PBS), cells were analyzed by flow
cytometry with excitation and emission wavelengths of 495 and
525 nm, respectively. Cells treated with 100 mMH 2O2 for 1 h
were used as a positive control [5].
Measurement of MMP. MMP was assessed by the retention
of Rh123, a membrane-permeable fluorescent cationic dye that is
selectively taken up by mitochondria. Its fluorescence intensity is
proportional to MMP levels. Cells treated with b-elemene
piperazine derivatives for various times were collected and
incubated with 0.3 mg/mL Rh123 in the dark for 20 min at
room temperature. After washing with PBS, the cells were
analyzed by flow cytometry with excitation and emission
wavelengths of 495 and 535 nm, respectively.
Western blot analysis. Protein extracts (50 mg) prepared
with RIPA lysis buffer [50 mmol/L Tris-HCl, 150 mmol/L NaCl,
0.1% sodium dodecyl sulfate (SDS), 1% NP-40, 0.5% sodium
deoxycholate, 1 mmol/L phenylmethyl sulfonyl fluoride (PMSF),
100 mmol/L leupeptin, and 2 mg/mL aprotinin, PH 8.0] were
separated on an 8% or 12% SDS-polyacrylamide gel and
transferred to nitrocellulose membranes. The membranes were
stained with 0.2% Ponceau S red to assure equal protein loading
and transfer. After blocking with 5% nonfat milk, the membranes
were incubated with a specific antibody overnight at 4uC.
Immunocomplexes were visualized by ECL Western Blotting
Detection reagents (Amersahm Biosciences, UK). Protein contents
in the lysate were determined by the Bradford protein binding
assay [9].
RNA interference. FLIPS/L siRNA (sc-35388) and a negative
control siRNA (sc-37007) were purchased from Santa Cruz
Biotechnology, Inc. siRNA was transfected into the K562 cells
by electroporation (Amaxa, Gaithersburg, MD) following the
manufacturer’s instructions. Briefly, 2610
6 cells were
electroporated in 100 mL nucleofector solution (Amaxa Reagent
V) containing 30 pmol of each siRNA using the preselected
Amaxa Program T-016. siRNA transfected cells were plated in a
Apoptosis Induction by b-Elemene Derivatives
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10% FBS for 15 h and subsequently further treated with or
without 10 mM DX1 for 24 h. Cells treated with or without DX1
were harvested for Western blotting analysis.
Statistics
The Student’s t-test (Microsoft Excel, Microsoft Corporation,
Seattle, WA) was performed to determine the significance between
groups. A P-value of less than 0.05 (P,0.05) was considered to be
statistically significant.
Results
b-elemene piperazine derivatives inhibit cell growth and
induce cytotoxicity in HL-60 cells
HL-60 cells were treated with various concentrations of b-
elemene piperazine derivatives for 4 days. The levels of cell
numbers and viable cells were determined. The concentrations
which inhibited 50% of cell growth (IG50) and killed half of the
cells (IC50) were calculated. DX1, DX2 and DX5 were more
potent than DX3 and DX4 in inhibiting cell growth and in
inducing cytotoxicity (Fig. 1A). All five derivatives were more
effective than b-elemene in inhibiting HL-60 cell growth (Fig. 1A).
The time- and dose-dependent effects of DX1 on cell growth and
viability of HL-60 cells are shown in Fig. 1B, 1C, 1D. DX1 at a
concentration of 10 mM killed about 60% of the cells after 24 h of
treatment as determined by trypan blue exclusion (Fig. 1C) and
MTT assay (Fig. 1D). DX1 at a concentration of 10 mM killed all
of the cells after 36 h of treatment determined by trypan blue
exclusion (Fig. 1C).
DX1 decreases MMP, increases H2O2 production and
induces apoptosis in HL-60 cells
To determine whether the cytotoxicity of DX1 is due to
induction of apoptosis, apoptotic cells were determined based on
morphologic examination after staining with AO and EB in HL-
Figure 1. The structures, the antiproliferative and cytotoxic effects of b-elemene piperazine derivatives in HL-60 cells. (A) The
substitutions of b-elemene piperazine derivatives and their IG50s and IC50s. HL-60 cells were treated with various concentrations of these
compounds for 4 days. The cell number and viability were determined. The drug concentrations that inhibited half of the cell growth (IG50) or that
killed half of the cells (IC50) were calculated. The data shown are the mean plus SE of three independent experiments. (B) Antiproliferative effects
of DX1. (C) Cytotoxicity of DX1 measured by trypan blue exclusion. (D) Cytotoxicity of DX1 measured by the MTT assay. HL-60 cells
were treated with the indicated concentrations of DX1 for the indicated times. Cell growth inhibition (B) and cytotoxicity (C&D) were determined as
described in Materials and Methods. The data shown are the mean plus SE of three independent experiments.
doi:10.1371/journal.pone.0015843.g001
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pattern (Fig. 2A). Apoptotic cells were detected in cultures after
treatment with 10 mM DX1 for 6, 9 and 12 h and after treatment
with 6, 8, 10 and 12 mM DX1 for 10 h. DX1 (12 mM ) induced
97% of cells to undergo apoptosis after 10 h of treatment. The
apoptosis induction ability of DX1 was further confirmed by
FACS analysis after staining with Annexin V/PI (Fig. 2B, 2C) and
determination of fragmented DNA (Fig. 2D).
H2O2 production was measured in HL-60 cells after DX1
treatment using a H2O2-sensitive fluorescent probe, DCFH-DA.
The effect of DX1 on MMP was determined by flow cytometry
using the cationic dye Rh123. DX1 induced a dose-dependent
production of H2O2 and a decrease in MMP (Fig. 2E & 2F). Time
course studies revealed that DX1 increased the amount of H2O2
as early as 2 h after beginning treatment (data not shown). These
data suggest that the mitochondrial-apoptotic pathway, probably
due to H2O2 production, is involved in the apoptosis induction by
DX1 treatment.
Antioxidants NAC and CAT partially inhibit DX1-induced
apoptosis
To evaluate the role of ROS accumulation in DX1-induced
apoptosis, we investigated the effects of antioxidants NAC and
CAT on DX1-induced apoptosis and on the decrease in MMP.
Pretreatment with antioxidants NAC and CAT prevented DX1-
induced H2O2 accumulation (Fig. 3A). However, pretreatment
with NAC and CAT only partially blocked the loss of MMP and
apoptosis due to DX1 treatment (Fig. 3B and 3C). These data
suggest that H2O2 production only plays a partial role in the
process of DX1-induced apoptosis.
Figure 2. Apoptosis induction, ROS production and the decrease in MMP by DX1 treatment in HL-60 cells. (A) Apoptotic cell levels
determined by morphological observation after AO/EB staining. HL-60 cells were treated with DX1 at the indicated concentrations for 10 h
or treated with DX1 at 10 mM for the indicated times. The percentage of apoptotic cells was determined morphologically using a fluorescence
microscope after staining with AO and EB. The data shown are the mean plus SE of three independent experiments. (B) Time-dependent and (C)
Dose-dependent apoptosis induction due DX1 treatment determined by FACS analysis after staining with Annexin V/PI. HL-60 cells
were treated with DX1 at 10 mM for the indicated times (B) or treated with DX1 at the indicated concentrations for 10 h (C). The percentage of
apoptotic cells was determined by FACS after staining with Annexin V. (D) Fragmented DNA. HL-60 cells were treated with DX1 at the indicated
concentrations for 10 h and total DNA was isolated. The levels of fragmented DNA was determined using staining with EB after electrophoresis in
agarose gel. M, DNA marker. (E) H2O2 production. HL-60 cells were labeled with 5 mM DCFH-DA fluorescent probe for 1 h and then treated with or
without DX1 at the indicated concentrations for 8 h. Oxidized DCF levels were analyzed using FACS as described in Materials and Methods. Open
peaks, untreated cells; shaded peaks, DX1-treated cells with the labeled concentrations. (F) MMP. HL-60 cells were treated with DX1 at the indicated
concentrations for 8 h. Alterations of MMP were determined according to changes in fluorescence density upon Rhodamine 123 loading as described
in Materials and Methods. Open peaks, untreated cells; shaded peaks, treated cells. The peak shift to left indicates a loss of MMP.
doi:10.1371/journal.pone.0015843.g002
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levels of c-FLIP protein
To explore the apoptotic machinery, the protein levels of Bid,
caspase-3, caspase-8, caspase-9, CD95, CD95L, c-FLIP, DR4,
DR5, PARP and TRAIL were determined in HL-60 cells after
treatment with several concentrations of DX1 using Western
blotting analyses. DX1 treatment induced a dose-dependent
reduction in the levels of pro-caspase-3, pro-caspase-8, Bid and
c-FLIP (Fig. 4A). DX1 treatment induced cleavage of caspase-8
and PARP (Fig. 4A). Activation of caspase-3 leads to the cleavage
of PARP. Caspase-8 can activate caspase-3 directly or indirectly
through cleavage of Bid followed by the activation of caspase-9.
Time-dependent induction of caspase-8 and caspase-9 cleavage
was determined (Fig. 4B). The cleaved fragments of both caspase-8
and caspase-9 were detected after 3 h of treatment with DX1
(Fig. 4B). These data suggest that both death receptor- and
mitochondrial-mediated apoptotic pathways are involved in DX1-
induced apoptosis. Caspase-8 activation by aggregated or ligated
death receptors is mediated through FADD [10]. The protein
levels of death receptors, DR4, DR5, CD95 and their ligands
TRAIL and CD95L were not increased in those cells treated with
DX1 (Fig. 4A). Neither CD95L neutralizing antibody NOK-1 nor
human recombinant DR5 (TRAIL R2)/Fc chimera protein
blocked the apoptosis induction by DX1 treatment (Fig. 4C).
The activation of caspase-8 is inhibited by c-FLIP [11]. Both the
long form c-FLIPL and the short form c-FLIPS were reduced after
treatment with DX1 (Fig. 4A). Jurkat subclones, I 2.1 cells, lacking
FADD, and I 9.2 cells, lacking caspase-8, were less sensitive to
DX1-induced apoptosis compared to their parental subclone, A3
as measured by observation of morphological changes after AO/
EB staining (Fig. 4D) and by FACS analysis after Annexin V/PI
staining (Fig. 4E). These data suggest that the activation of
caspase-8 plays a partial role in DX1-induced apoptosis. The
activation of caspase-8 by DX1 treatment is probably mediated by
decreases in c-FLIP levels, but not by the induction of death
receptor levels or by the ligation of the death receptors.
MG-132 enhances DX1-induced apoptosis in HL-60 cells
It has been shown that c-FLIP is degraded by a proteasome-
mediated pathway and that the proteasome inhibitor MG-132
blocked c-FLIP degradation in cells treated with several agents
[12,13]. Moreover, it also has been reported that MG-132
decreased the levels of c-FLIP and sensitized TRAIL-induced
apoptosis [14,15]. The effects of MG-132 on the apoptosis
induction and on c-FLIP levels were determined in HL-60 cells
by Western blotting analysis. HL-60 cells were responsive to MG-
132-induced apoptosis determined by PARP cleavage. The PARP
cleavage was observed after treatment with MG-132 at a
concentrations higher than 1 mM. MG132 decreased the levels
of both long and short forms of c-FLIP (Fig. 5A). MG-132 at
0.5 mM alone did not induce apoptosis or c-FLIP decrease and this
concentration was selected to test the effects of MG-132 on DX1-
induced apoptosis and c-FLIP downregulation (Fig. 5B, 5C).
MG132 at 0.5 mM by itself apparently did not induce apoptosis.
Figure 3. The antioxidants NAC and CAT block H2O2 production, but not on the loss of MMP by DX1 treatment in HL-60 cells.
(A) H2O2 levels; (B) MMP; (C) Apoptotic cells. HL-60 cells were pretreated with or without NAC (10 mM) or CAT (500 U/ml) for 4 h followed by
treatment with 10 mM DX1 for 8 h. The levels of H2O2 and MMP were measured using FACS as described in Materials and Methods. Open peaks,
untreated cells; shaded peaks, DX1-treated cells with the labeled agents (A and B). The percentage of apoptotic cells was determined by flow
cytometric analysis after PI staining as described in Materials and Methods.
doi:10.1371/journal.pone.0015843.g003
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whereas combination treatment of MG-132 with DX1 induced
apoptosis in 74.6% of the cells (Fig. 5B). Correlated with this
apoptosis induction, the cleavage of PARP and caspase-8 as well as
decreases in c-FLIP levels were enhanced by the combination
treatment (Fig. 5C). Time-dependent results revealed that MG-
132 enhanced DX1-induced decrease in c-FLIP levels after 6 h
treatment (Fig. 5D).
DX1-induced apoptosis is correlated with the
downregulation of c-FLIP in NB4, HP100-1 and K562 cells
The abilities of DX-1 to induce apoptosis and to downregulate c-
FLIP were further investigated in three additional leukemia cell
lines. NB4 cells were as sensitive as HL-60 cells to DX1-induced
apoptosis (Fig. 6A). HP100-1 cells were less sensitive to DX1-
induced apoptosis compared to HL-60 and NB4 cells (Fig. 6A).
K562 cells did not respond to DX1-induced apoptosis at 10 mM
treatment for 10 h (Fig. 6A). However, DX1 induced apoptosis in
K562 cells at increased concentrations and prolonged incubation
times (data not shown).The cleavage of PARP and caspase-8as well
as the decrease in the c-FLIP levels occurred in NB4 and HP100-1
cells, but not in K562 cells (Fig. 6B). Therefore, these processes
correlate with the sensitivity to DX1-induced apoptosis at 10 mM
treatment in these three cell lines (Fig. 6A). MG-132 enhanced
DX1-induced apoptosis at 8 mM in NB4 and HP100-1 cells at 12 h,
but in K562 cells only at treatment times of 36 h or longer (Fig. 6C).
MG-132 plus DX1 augmented to induce cleavage of both PARP
and caspase-8 and to decrease the levels of c-FLIP in K562 cells
after 36 h of treatment (Fig. 6D). To further determine the role of c-
FLIP in DX1-induced apoptosis, the c-FLIP levels were knocked-
down using siRNA. Augmented PARP cleavage was observed in
K562 cells transfected with c-FLIP siRNA (Fig. 6E).
Figure 4. Caspase-8 activation and its role in DX1-treated cells. (A) Western blot analyses of protein levels. HL-60 cells were treated
with DX1 at the indicated concentrations for 10 h. The levels of each protein as indicated were detected using a specific antibody as described in
Materials and Methods. (B) Time-dependent cleavage of caspase-8 and -9. HL-60 cells were treated with DX1 at 10 mM for the indicated times.
(C) The effects of NOK-1 and TRAIL-R2/Fc on DX1-induced apoptosis. HL-60 cells were pretreated with 1 mg/ml NOK-1 or 1 mg/ml TRAIL-R2/
Fc for 4 h followed by treatment of 10 mM DX1 for 10 h. The percentage of apoptotic cells was determined morphologically using a fluorescence
microscope after staining with AO and EB. The data shown are the mean plus SE of three independent experiments. (D&E ) Apoptosis induction
of DX1 in FADD- and caspase-8- deficient Jurkat subclones. FADD-deficient clone I 2.1, caspase-8-deficient clone I 9.2 and parental clone A3
were treated with DX1 at the indicated concentrations for 10 h. The percentage of apoptotic cells was determined morphologically using a
fluorescence microscope after staining with AO/EB (D) and by FACS after staining with Annexin V/PI (E). The data shown (D) are the mean plus SE of
three independent experiments. * P,0.05, I 9.2 cells treated with DX1 compared to A3 cells treated with DX1; ** P,0.01, I 2.1 cells treated with DX1
compared to A3 cells treated with DX1.
doi:10.1371/journal.pone.0015843.g004
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inducing apoptosis and in decreasing c-FLIP levels in
HL-60 cells
The apoptosis induction abilities of DX2, DX3, DX4 and DX5
were compared to that of DX1 in HL-60 cells. DX2 and DX5 had
similar activities as that of DX1 in apoptosis induction. DX1, DX2
and DX5 at 12 mM induced more than 80% of HL-60 cells to
undergo apoptosis after 10 h of treatment (Fig. 7A). DX3 and
DX4 at 12 mM only induced less than 15% of cells to undergo
apoptosis after 10 h of treatment (Fig. 7A). DX3 and DX4 at
12 mM induced higher percentages of apoptotic cells at prolonged
incubation times (data not shown). At 10 mM, DX2 and DX5, but
not DX3 or DX4, induced cleavage of PARP and caspase-8, and
decreased the levels of c-FLIP (Fig. 7B). MG-132 plus DX3 or
DX4 had augmented effects in inducing apoptosis and in
decreasing c-FLIP levels compared to any of these agents alone
(Fig. 7C&7D). DX1, DX2 and DX5 contain a secondary amino
moiety (Fig. 1). The hydrogen at position 4 of piperazine was
substituted by an ethyl and an isopropyl in DX3 and DX4,
respectively (Fig. 1). Based on their abilities to induce apoptosis
and to decrease c-FLIP levels, it seems that the secondary amino
moiety is an important enhancing group for the biological activity
of these b-elemene derivatives.
Discussion
b-Elemene inhibits cell growth only at high concentrations.
Previously we found that b-elemene substituted with a tryptophan
methyl ester improved its antiproliferative effects and induced
Figure 5. MG-132 enhanced apoptosis induction and caspase-8 cleavage due to DX1 treatment in HL-60 cells. (A) Western blot
analysis of PARP, caspase-8 and c-FLIP levels in HL-60 cells treated with MG-132. HL-60 cells were treated with DMSO (control), MG-132 at
the indicated concentrations for 10 h. (B) Apoptotic cells determined morphologically. HL-60 cells were treated with DMSO (control), MG-132
0.5 mM, DX1 8 mM or MG132 plus DX1 for 10 h. The percentage of apoptotic cells was determined by morphological observation after AO/EB staining
as described in Materials and Methods. * P,0.05 and ** P,0.01 compared to cells treated without MG132. (C) Western blot analysis of PARP,
caspase-8, c-FLIP, DR4 and DR5 proteins. HL-60 cells were treated with DMSO (control), MG-132 0.5 mM, DX1 8 mM or MG132 plus DX1 for 10 h.
(D) Time-dependent decrease of c-FLIP levels due to treatment by MG-132 plus DX1 in HL-60 cells. Lane 1, control cells; Lane 2, cells
treated with 0.5 mM MG-132 for 9 h; Lane 3, cells treated with 8 mM DX1 for 3 h; Lane 4, cells treated with 8 mM DX1 plus 0.5 mM MG-132 for 3 h; Lane
4, cells treated with 8 mM DX1 for 6 h; Lane 6, cells treated with 8 mM DX1 plus 0.5 mM MG-132 for 6 h; Lane 7, cells treated with 8 mM DX1 for 9 h;
Lane 8, cells treated with 8 mM DX1 plus 0.5 mM MG-132 for 9 h. The levels of each protein were detected using specific antibodies as described in
Materials and Methods.
doi:10.1371/journal.pone.0015843.g005
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[16]. In this study, we found that b-elemene substituted with a
piperazine was even more effective than b-elemene substituted
with a tryptophan methyl ester in inducing apoptosis. These
compounds acted through both ROS production and c-FLIP
reduction. The IG50 of these b-elemene derivatives substituted
with a piperazine was decreased to less than 10 mM (Fig. 1A).
Based on the cell growth inhibition abilities of DX1 to DX5, the
substitution with one (DX1) or two methyl groups (DX2) of
piperazine does not evidently influence the antiproliferative and
cytotoxic effects of these piperazine derivatives. However,
replacement of the hydrogen of the C-4 of piperazine with an
ethyl (DX3) or an isopropyl (DX4) decreases the antiproliferative
and cytotoxic effects compared to those of DX1, DX2 and DX5
which have a hydrogen at C-4. DX1, DX2 and DX5 induced
evident apoptosis at concentrations of 6–10 mM after treatment for
10 h (Fig. 7A). DX3 and DX4 induced apoptosis at higher
concentrations and more prolonged incubation times (data not
shown). These data suggest that the apoptosis induction of these
compounds is an important mechanism for their ability to induce
cytotoxicity.
DX1 was used to explore the mechanism of apoptosis induction.
It is known that death receptor and mitochondrial apoptotic
pathways play important roles in apoptosis induction due to
chemotherapeutic agents [17,18,19]. Several agents have been
found to induce the mitochondrial-mediated apoptotic pathway
through the generation of ROS which decreases the MMP which
then leads to activation of caspase-3 [5,20]. DX1 increased the
production of ROS, decreased MMP levels, and activated caspase-
3 in HL-60 cells (Fig. 2). To investigate the role of ROS in DX1-
induced apoptosis, antioxidants NAC and CAT were used.
Although both NAC and CAT could prevent the ROS production
Figure 6. Apoptosis induction, caspase-8 cleavage, and the decrease in c-FLIP levels due to DX1 treatment in NB4, HP100-1 and
K562 cells. (A) Apoptotic cells. HL-60, HP100-1, NB4 and K562 cells were treated with 10 mM DX1 for 9 h. The percentage of apoptotic cells was
determined by morphological observation after AO/EB staining as described in Materials and Methods. (B) The protein levels and cleavage of
PARP, caspase-8 and c-FLIP. NB4, HP100-1 and K562 cells were treated with or without 10 mM DX1 for 10 h. The levels of each protein were
detected using specific antibodies as described in Materials and Methods. (C) MG-132 enhancement of DX1-induced apoptosis. Cells were
treated with DMSO (control), MG-132 0.5 mM, DX1 8 mM or MG132 plus DX1 for 10 h (NB4 and HP100-1 cells) or for 36 h (K562 cells). The percentage
of apoptotic cells was determined morphologically after AO/EB staining as described in Materials and Methods. * P,0.05 compared to cells treated
with DX1 alone. (D) MG-132 enhancement of DX1-induced cleavage of PARP and caspase-8 in K562 cells. K562 cells were treated with
DMSO (control), MG-132 0.5 mM, DX1 8 mM or MG-132 plus DX1 for 36 h. The levels of each protein were detected using specific antibodies as
described in Materials and Methods. (E) The influence of c-FLIP siRNA on DX1-induced cleavage of PARP and caspase-8 in K562 cells.
K562 cells were incubated with control siRNA or c-FLIP siRNA for 15 h and then treated with or without 10 mM DX1 for 24 h. The levels of each
protein were deteced using specific antibodies as described in Materials and Methods.
doi:10.1371/journal.pone.0015843.g006
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effects in preventing cells from undergoing DX1-induced apoptosis
(Fig. 3). Since both NAC and CAT only partially block DX1-
induced decrease in MMP, it seems that the decrease in MMP
after DX1 treatment, at least in part, is mediated through an
ROS-independent pathway (Fig. 3). HP100-1 cells, which are
resistant to H2O2 [6,21], are responsive to DX1 treatment
(Fig. 6A). These data suggest that ROS production only plays a
partial role in DX1-induced apoptosis. Thus, the action of DX1 is
different from that of N-(b-elemene-13-yl)tryptophan methyl ester
which induced apoptosis only by increasing ROS [16].
The death receptor-mediated pathway can also lead to decreases
in MMP through cleavage of BID dueto activatedcaspase-8[22]. It
has been found that several agents could activate caspase-8 through
increasing the levels of death receptors [23,24,25,26]. DX1
treatment activated caspase-8 based on the determination of its
cleavage and decrease in the levels of Bid (Fig. 4A). Therefore, the
decrease in MMP levels by DX1 treatment could be partly due to
cleaved Bid. Previously we have found that boswellic acids induced
apoptosis by activated caspase-8 due to induction of DR4 and DR5
proteins [27,28]. However, the levels of DR4, DR5 and CD95 as
well as their ligands CD95L and TRAIL were not increased after
DX1 treatment (Fig. 4A). Neither CD95L neutralizing antibody
NOK-1 nor human recombinant DR5 (TRAIL R2)/Fc chimera
protein was able to block DX1-induced apoptosis (Fig. 4C). These
data suggest that DX1 activates caspase-8 through a pathway
independent of the regulation of death receptor levels and their
activation. c-FLIP has been found to inhibit the activation of
caspase-8. Severalother agents havebeenfound to activate caspase-
8 by decreasing the levels of c-FLIP[29,30,31]. The proteinlevels of
both c-FLIPL and c-FLIPS were reduced by DX1 treatment in a
concentration-dependent pattern that was correlated with the
cleavage of both caspase-8 and PARP (Fig. 4A). DX1 treatment
induced cleavage of caspase-8 and PARP and decreased c-FLIP
levels in NB4 and HP100-1 cells, but not in K562 cells (Fig. 6B).
DX2 and DX5 treatments decreased the levels of c-FLIP and
induced the cleavage of caspase-8 and PARP in HL-60 cells
(Fig. 7B). DX3 and DX4 treatment did not decrease the levels of c-
FLIPnorinducethecleavage ofcaspase-8and PARP inHL-60 cells
(Fig. 7B). FADD-deficient and caspase-8-deficient Jurkat subclones
were less sensitive to DX1-induced apoptosis (Fig. 4D, 4E).
Silencing c-FLIP augmented DX1-induced apoptosis in K562 cells
(Fig. 6E). These data suggest the activation of caspase-8 is probably
mediated through downregulation of c-FLIP and that activated
Figure 7. Apoptosis induction, caspase-8 cleavage, and the reduction of c-FLIP levels by treatment with DX2, DX3, DX4 and DX5 in
HL-60 cells. (A) Apoptotic cells. HL-60 cells were treated with DX1, DX2, DX3, DX4 or DX5 at the indicated concentrations for 10 h. The
percentage of apoptotic cells was determined using a fluorescence microscope after staining with AO and EB as described in Materials and Methods.
The data shown are the mean plus SE of three independent experiments. (B) The protein levels and cleavage of PARP, caspase-8 and c-FLIP.
HL-60 cells were treated with 8 or 10 mM of each compound for 10 h. The levels of each protein were detected using a specific antibody as described
in Materials and Methods. (C) MG-132 enhancement of DX3- and DX4-induced apoptosis. HL-60 cells were treated with DMSO (control), MG-
132 0.5 mM, DX3/DX4 or MG132 plus DX3/DX4 at the indicated concentrations for 10 h. The percentage of apoptotic cells was determined using a
fluorescence microscope after staining with AO and EB as described in Materials and Methods. * P,0.05 and ** P,0.01 compared to cells treated
without MG132. (D) MG-132 enhancement of DX3- and DX4-induced cleavage of PARP and caspase-8 as well as the reduction in c-
FLIP levels. HL-60 cells were treated with DMSO (control), MG-132 0.5 mM, DX3 8 mM, DX4 8 mM, MG-132 plus DX3 or MG-132 plus DX4 for 10 h. The
levels of each protein were detected using a specific antibody as described in Materials and Methods.
doi:10.1371/journal.pone.0015843.g007
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by these compounds.
c-FLIP is known to be regulated by a ubiquitin-proteasome
mechanism, and several cancer therapeutic agents have been
found to induce downregulation of c-FLIP through this mecha-
nism [32,33,34]. MG-132 has been reported to inhibit the
decrease of c-FLIP levels induced by several agents in cancer cells
[13,35,36]. However, it also has been reported that MG-132
decreased c-FLIP levels and enhanced TRAIL-induced apoptosis
in prostate cancer cells and chronic lymphocytic leukemia cells
[14,15]. The difference of MG-132 action on c-FLIP levels may be
cell type- and/or agent-dependent. In HL-60 cells MG-132 alone
induced apoptosis and decreased the levels of c-FLIP at a
concentration higher than 1 mM (Fig. 5A). We examined the
effects of DX1 on the levels of c-FLIP and apoptosis induction in
the presence and absence of MG-132 at a lower concentration.
MG-132, at a concentration of 0.5 mM, weakly decreased c-FLIP
levels and augmented DX1 induction of apoptosis and its ability to
decrease c-FLIP levels (Fig. 5C, 5D). Our data indicate that MG-
132 enhances the effects of these DX compounds to induce
apoptosis by decreasing c-FLIP levels in these leukemia cells. Since
the concentrations of MG-132 used here are very low, it is possible
that reduction of c-FLIP by MG-132 is independent of its ability of
inhibiting proteasome activity. The mechanism of inducing
downregulation of c-FLIP levels by DX and MG-132 in leukemia
cell lines needs to be further studied.
In summary, the present study reports the apoptotic effects
and the mechanisms of action of five novel b-elemene pipera-
zine derivatives. They induce apoptosis through production of
ROS and decrease in c-FLIP levels and, thus, activate both
death receptor-mediated and mitochondrial-mediated apoptotic
pathways.
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